(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
CGT9486+舒尼替尼与舒尼替尼在局部晚期、不可切除或转移性胃肠道间质瘤受试者中的 3 期随机、开放标签、多中心临床研究
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
研究概览
地位
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Cogent Biosciences
- 电话号码:617-945-5576
- 邮箱:peakinfo@cogentbio.com
学习地点
-
-
-
Aarhus、丹麦、8200
- 主动,不招人
- Aarhus University Hospital
-
-
-
-
-
Calgary、加拿大、T2N 4N2
- 招聘中
- Tom Baker Cancer Center
-
Montreal、加拿大、HIT 2M4
- 主动,不招人
- Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1Z2
- 招聘中
- Alberta Health Services Cross Cancer Institute
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- 招聘中
- Princess Margaret Hospital
-
-
-
-
-
Debrecen、匈牙利、4032
- 主动,不招人
- Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
-
-
-
-
-
Kaohsiung City、台湾、83301
- 主动,不招人
- Chang Gung Memorial Hospital - Kaohsiung Branch
-
New Taipei City、台湾、10002
- 主动,不招人
- National Taiwan University Hospital
-
Taichung、台湾、40447
- 主动,不招人
- China Medical University Hospital
-
Taipei、台湾、11217
- 主动,不招人
- Taipei Veterans General Hospital (VGHTP)
-
Taoyuan、台湾、33305
- 主动,不招人
- Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
-
-
-
-
-
Aguascalientes、墨西哥、20116
- 撤销
- Centro de Investigacion Medica Aquascalientes (CIMA)
-
Monterrey、墨西哥、64710
- 主动,不招人
- I Can Oncology Center SA De CV
-
Oaxaca City、墨西哥、68000
- 撤销
- Oaxaca Site Management Organization S.C.
-
-
-
-
-
Campinas、巴西、130.83-888
- 主动,不招人
- Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
-
Rio de Janeiro、巴西、20.230-130
- 主动,不招人
- lnstituto Nacional de Cancer - INCA
-
São Paulo、巴西、09060-650
- 主动,不招人
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
-
-
-
-
-
Bad Saarow、德国、15526
- 主动,不招人
- Helios Klinikum Bad Saarow
-
Berlin、德国、13125
- 主动,不招人
- Helios Klinikum Berlin-Buch
-
Essen、德国、45147
- 主动,不招人
- Universitaetsklinikum Essen
-
Hamburg、德国、20246
- 主动,不招人
- Universitaetsklinikum Hamburg-Eppendorf
-
Hanover、德国、30625
- 主动,不招人
- Medizinische Hochschule Hannover- Urology Oncology
-
Mannheim、德国、68167
- 主动,不招人
- Universitaetsmedizin Mannheim
-
-
-
-
-
Aviano、意大利、33081
- 主动,不招人
- Centro Riferimento Oncologico - Aviano
-
Bologna、意大利、40138
- 主动,不招人
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
-
Brescia、意大利、25123
- 主动,不招人
- ASST degli Spedali Civili di Brescia
-
Candiolo、意大利、10060
- 撤销
- IRCCS La Fondazione e l'Istituto di Candiolo
-
Florence、意大利、50134
- 主动,不招人
- Azienda Ospedaliero-Universitaria Careggi
-
Meldola、意大利、47014
- 主动,不招人
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
-
Milan、意大利、20133
- 主动,不招人
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan、意大利、20141
- 主动,不招人
- Istituto Europeo di Oncologia
-
Palermo、意大利、90127
- 主动,不招人
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
Roma、意大利、00128
- 主动,不招人
- Policlinico Universitario Campus Bio-Medico
-
Rozzano、意大利、20089
- 主动,不招人
- Istituto Clinico Humanitas
-
Verona、意大利、31726
- 主动,不招人
- Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
-
-
-
-
-
Bergen、挪威、5021
- 主动,不招人
- Haukeland University Hospital - Bergen
-
Oslo、挪威、0310
- 主动,不招人
- Oslo University Hospital
-
-
-
-
-
Brno、捷克语、65653
- 主动,不招人
- Masarykuv onkologicky ustav
-
Hradec Králové、捷克语、500 05
- 撤销
- Fakultni nemocnice Hradec Kralove
-
Olomouc、捷克语、77900
- 主动,不招人
- Fakultni nemocnice Olomouc - Oncology clinic
-
-
-
-
-
Santiago、智利、7500921
- 主动,不招人
- Instituto Oncologico FALP
-
Santiago、智利、7560908
- 主动,不招人
- Centro de Oncologia de Precision, Universidad Mayor
-
-
-
-
-
Bordeaux、法国、33076
- 主动,不招人
- Institut Bergonie
-
Lille、法国、59000
- 主动,不招人
- Centre Oscar Lambret
-
Lyon、法国、69008
- 主动,不招人
- Centre Leon Berard
-
Marseille、法国、13005
- 主动,不招人
- AP-HM - Hôpital de la Timone
-
Rennes、法国、35042
- 主动,不招人
- Centre Eugene Marquis
-
Saint-Herblain、法国、44800
- 主动,不招人
- ICO St-Herblain
-
Toulouse、法国、31400
- 主动,不招人
- CHU de Toulouse - Hospital Rangueil
-
Villejuif、法国、94805
- 主动,不招人
- Gustave Roussy
-
-
-
-
-
Brzozów、波兰、36-200
- 主动,不招人
- Szpital Specjalistyczny w Brzozowie
-
Bydgoszcz、波兰、85-796
- 撤销
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka
-
Gliwice、波兰、44-102
- 主动,不招人
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
-
Warsaw、波兰、02-781
- 主动,不招人
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
-
-
-
-
-
Bankstown、澳大利亚、2200
- 主动,不招人
- Bankstown-Lidcombe Hospital
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚、6009
- 主动,不招人
- Sir Charles Gairdner Hospital
-
-
-
-
-
Lund、瑞典、22185
- 主动,不招人
- Skane University Hospital Lund
-
Solna、瑞典、171 76
- 主动,不招人
- Karolinska University Hospital
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35249
- 撤销
- University of Alabama at Birmingham
-
-
Arizona
-
Scottsdale、Arizona、美国、85259
- 招聘中
- Mayo Clinic
-
Tucson、Arizona、美国、85719
- 主动,不招人
- University of Arizona- Cancer Center
-
-
California
-
Duarte、California、美国、91010
- 招聘中
- City of Hope
-
Los Angeles、California、美国、90404
- 主动,不招人
- University of California, Los Angeles (UCLA)
-
San Diego、California、美国、92093
- 招聘中
- University of California, San Diego (UCSD)
-
San Francisco、California、美国、94158
- 主动,不招人
- University of California, San Francisco
-
-
Colorado
-
Denver、Colorado、美国、80204
- 招聘中
- University of Colorado Denver
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- 招聘中
- MedStar Washington Hospital Center
-
-
Florida
-
Jacksonville、Florida、美国、32224
- 招聘中
- Mayo Clinic Jacksonville
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami - Sylvester Comprehensive Cancer Center
-
Orange City、Florida、美国、32763
- 撤销
- Mid Florida Hematology and Oncology Center
-
Orlando、Florida、美国、32806
- 招聘中
- Orlando Health Cancer Institute
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern University
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- 招聘中
- University of Iowa Hospital and Clinics
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 主动,不招人
- University of Kansas Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic
-
-
Missouri
-
St Louis、Missouri、美国、63130
- 招聘中
- Washington University
-
-
Nebraska
-
Omaha、Nebraska、美国、68114
- 招聘中
- Nebraska Methodist Hospital
-
-
New York
-
Buffalo、New York、美国、14203
- 主动,不招人
- Roswell Park Comprehensive Cancer Center
-
New York、New York、美国、10021
- 招聘中
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- 招聘中
- Duke University
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- The Cleveland Clinic Foundation
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University Comprehensive Cancer Center
-
Toledo、Ohio、美国、43614
- 撤销
- University of Toledo Medical Center
-
-
Oregon
-
Portland、Oregon、美国、97239
- 招聘中
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19111
- 招聘中
- Fox Chase Cancer Center
-
Pittsburgh、Pennsylvania、美国、15232
- 招聘中
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
-
Tennessee
-
Knoxville、Tennessee、美国、37920
- 撤销
- University of Tennessee
-
Nashville、Tennessee、美国、37232
- 招聘中
- Vanderbilt University Medical Center
-
-
Texas
-
Houston、Texas、美国、77030-4009
- 招聘中
- The University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle、Washington、美国、98109
- 主动,不招人
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、美国、53705
- 招聘中
- University of Wisconsin - Carbone Cancer Center
-
-
-
-
-
Cambridge、英国、CB2 0QQ
- 主动,不招人
- Cambridge Addenbrooke's Hospital
-
Glasgow、英国、G12 0YN
- 撤销
- Beatson, West of Scotland Cancer Centre
-
London、英国、NW1 2PG
- 主动,不招人
- University College London Hospital
-
London、英国、SW3 6JJ
- 主动,不招人
- Royal Marsden Hospital - Surrey
-
London、英国、SE1 9RT
- 撤销
- Guy's Hospital
-
Manchester、英国、M20 4BX
- 主动,不招人
- The Christie NHS Foundation Trust
-
Sheffield、英国、S10 2SJ
- 主动,不招人
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Amsterdam、荷兰、1066 CX
- 主动,不招人
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
-
Groningen、荷兰、9713 GZ
- 主动,不招人
- UMC Groningen
-
Nijmegen、荷兰、6525 GA
- 主动,不招人
- Stichting Radboud Universitair Medisch Centrum
-
Rotterdam、荷兰、3015 GD
- 主动,不招人
- Erasmus MC
-
-
-
-
-
Barcelona、西班牙、08035
- 主动,不招人
- Hospital Universitario Vall d'Hebron
-
Barcelona、西班牙、08041
- 撤销
- Hospital de la Santa Creu i Sant Pau Barcelona
-
Barcelona、西班牙、08908
- 主动,不招人
- Institut Catala d'Oncologia - L'Hospitalet
-
El Palmar、西班牙、30120
- 撤销
- Hospital Clinico Universitario Virgen de la Arrixaca
-
Madrid、西班牙、28041
- 主动,不招人
- Hospital Universitario 12 de Octubre
-
Madrid、西班牙、28040
- 主动,不招人
- Hospital Clinico San Carlos
-
Madrid、西班牙、28007
- 主动,不招人
- Hospital General Universitario Gregorio Maranon
-
Madrid、西班牙、28040
- 主动,不招人
- Hospital Fundación Jiménez Díaz
-
Santiago de Compostela、西班牙、15706
- 主动,不招人
- Hospital Clinico Universitario de Santiago de Compostela
-
Seville、西班牙、41013
- 主动,不招人
- Hospital Universitario Virgen del Rocio
-
Zaragoza、西班牙、50009
- 撤销
- Hospital Universitario Miguel Servet
-
-
-
-
-
Buenos Aires、阿根廷、C1426ANZ
- 主动,不招人
- Instituto Alexander Fleming
-
Córdoba、阿根廷、X5000HWE
- 主动,不招人
- Instituto Oncologico de Cordoba (IONC)
-
-
-
-
-
Seoul、韩国、03080
- 主动,不招人
- Seoul National University Hospital
-
Seoul、韩国、06351
- 主动,不招人
- Samsung Medical Center
-
Seoul、韩国、08308
- 主动,不招人
- Korea University Guro Hospital
-
Seoul、韩国、05505
- 主动,不招人
- Asan Medical Center
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韩国、10408
- 撤销
- National Cancer Center
-
-
-
-
-
Central、香港
- 撤销
- Humanity & Health Clinical Trial Centre
-
Jordon、香港
- 主动,不招人
- Hong Kong United Oncology Centre
-
Shatin、香港
- 主动,不招人
- Prince of Wales Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)
-
Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)
-
Participants must have received the following treatment:
- DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
- Part 1b: Treatment with ≥2 prior TKI for GISTs
- Part 2: Prior treatment with imatinib only
- GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
-
Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)
-
Eastern Cooperative Oncology Group (ECOG) Status
- 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
- 0 to 1 (GIST 1L Substudy)
-
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Key Exclusion Criteria:
- Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
- Clinically significant cardiac disease
- Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
- Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
- Any active bleeding excluding hemorrhoidal or gum bleeding
- Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
- Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
- Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
- Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1a
Bezuclastinib plus sunitinib 37.5 mg once a day (QD) |
Participants will receive bezuclastinib orally until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
实验性的:Part 2 - Experimental Group
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
有源比较器:Part 2 - Control Group
Sunitinib 37.5 mg QD |
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
实验性的:Part 1b - DDI Cohort 1
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
实验性的:Part 1b - DDI Cohort 2
Sunitinib 37.5 mg QD plus bezuclastinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
实验性的:DDI Substudy (Midazolam)
Midazolam, bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. Participants will receive a single-dose of midazolam on Day 1 and Day 15 |
|
实验性的:GIST 1L Substudy
Bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
其他名称:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
其他名称:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1a - pharmacokinetics - Cmax
大体时间:16 days
|
Maximum plasma concentration (Cmax) |
16 days
|
|
Part 1a - pharmacokinetics - AUC
大体时间:16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
Part 1b - pharmacokinetics - Cmax
大体时间:14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
|
Part 1b - pharmacokinetics - AUC
大体时间:14 days
|
Area under the plasma concentration-time curve (AUC) |
14 days
|
|
Part 1b - pharmacokinetics - Tmax
大体时间:14 days
|
Time to maximum observed plasma concentration (Tmax) |
14 days
|
|
Part 2 - Progression Free Survival (PFS)
大体时间:Approximately 48 months
|
Time from first dose to documented disease progression or death due to any cause, whichever occurs first |
Approximately 48 months
|
|
DDI Substudy - pharmacokinetics - AUC
大体时间:16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
DDI Substudy - pharmacokinetics - Cmax
大体时间:14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
All Study Parts - observing the safety of each treatment regimen.
大体时间:Approximately 48 months
|
Incidence and severity of Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
大体时间:Approximately 48 months
|
Incidence and severity of Serious Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
大体时间:Approximately 48 months
|
Incidence of Adverse Events leading to dose modifications from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
大体时间:Approximately 48 months
|
Change from baseline in laboratory results |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
大体时间:Approximately 48 months
|
Time from first dose to death due to any cause |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
大体时间:Approximately 48 months
|
Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
大体时间:Approximately 48 months
|
Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks |
Approximately 48 months
|
|
Part 1a, Part 1b. Part 2 - Time to response (TTR)
大体时间:Approximately 48 months
|
Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
大体时间:Approximately 48 months
|
Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first |
Approximately 48 months
|
|
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
大体时间:Approximately 48 months
|
Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms. |
Approximately 48 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CGT9486-21-301
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.